Astria Therapeutics enters $150M ATM equity offering agreement with Jefferies

Astria Therapeutics, Inc.

Up to $150M of common stock may be sold through Jefferies as sales agent in at-the-market offerings.
Jefferies receives up to 3.0% commission; company reimburses up to $75K legal expenses.
Company has no obligation to sell shares; either party may terminate at any time.
Shares offered pursuant to existing shelf registration statement on Form S-3.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Astria Therapeutics, Inc. entered into Open Market Sale Agreement with Jefferies LLC valued at up to $150,000,000 (effective 2024-03-04).

Action: entry
Agreement: atm program
Counterparty: Jefferies LLC
Value: up to $150,000,000
Effective: 2024-03-04

Exact text from the filing

On March 4, 2024, Astria Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an Open Market Sale Agreement SM (the “Sales Agreement”) with Jefferies LLC (“Jefferies”) pursuant to which the Company may offer and sell shares of its common stock, $0.001 par value per share, from time to time through Jefferies as its sales agent.

View on SEC.gov

737 material agreements filed in the last 30 days. Browse all material agreements →

Source: SEC EDGAR

accession 0001104659-24-030539

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.